Compass Therapeutics Inc. stocks have been trading up by 8.19 percent, driven primarily by positive clinical trial advancement news.
Click Here for a Millionaire's POV on Trading CMPX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Tovecimig plus paclitaxel beat paclitaxel alone on response rate and progression‑free survival in second‑line biliary tract cancer, with a clean safety profile that confirms biological activity.
- Overall survival in COMPANION‑002 missed in the intent‑to‑treat population, but heavy crossover to tovecimig muddies how big the real survival benefit might be.
- CMPX collapsed roughly 56–63% to near $2 levels as traders focused on regulatory uncertainty and the headline overall survival miss.
- Most covering firms cut price targets but kept Buy/Outperform ratings on CMPX, with consensus targets still in the low‑teens versus a depressed share price.
- Compass Therapeutics plans FDA talks, including a targeted pre‑BLA meeting around mid‑2026, making regulatory interpretation of the crossover data the next key catalyst for CMPX.
Live Update At 12:32:58 EDT: On Friday, May 01, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending up by 8.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CMPX has been through a blender on the chart. Before the COMPANION‑002 readout, Compass Therapeutics traded in a tight $5–$6 range. Once the mixed biliary tract cancer data hit, CMPX fell off a cliff, dropping from a close of $5.03 on 2026/04/24 to the mid‑$1s within days. That kind of multi‑day slide is classic biotech headline risk.
The recent daily tape shows CMPX trying to stabilize. After tagging intraday lows near $1.61 on 2026/04/27, the stock has been grinding between roughly $1.67 and $1.98, with a latest close around $1.915. On the intraday 5‑minute chart, CMPX is basically chopping between $1.86 and $1.95, showing liquidity but no decisive trend yet. This is a textbook post‑crash consolidation.
More Breaking News
- CRSP Stock Firms Up As ARK Support And Needham Event Draw Traders
- NU Stock On Watch As TikTok Targets Brazil Fintech
- XXII Stock Draws Traders As VLN Growth Story Accelerates
- SLNH Stock Under Pressure As Share Resale Wave Builds
Under the hood, Compass Therapeutics remains a clinical‑stage story. The company posted a quarterly net loss of about $15.7M, with negative EBITDA around $19.8M and operating cash burn of roughly $13.3M. That sounds scary, but CMPX ended the period with about $31.2M in cash and $208.9M when including short‑term investments, plus a very light debt load and a current ratio near 15. In plain English, Compass Therapeutics has runway, low leverage, and a high‑risk, high‑reward profile that traders know well in small‑cap biotech.
Why Traders Are Watching CMPX After The Crash
This whole CMPX story starts with COMPANION‑002. Compass Therapeutics reported that its antibody tovecimig, combined with paclitaxel, beat paclitaxel alone in second‑line unresectable or metastatic biliary tract cancer. The combo delivered a statistically significant jump in overall response rate, 17.1% versus 5.3%, and nearly doubled progression‑free survival from 2.6 months to 4.7 months. Safety looked acceptable. That tells traders tovecimig is doing something real in a very tough cancer.
But Wall Street trades headlines, and the headline was brutal: in the intent‑to‑treat analysis, overall survival did not improve. CMPX then saw a more than 60% selloff in a single news cycle. The nuance comes from trial design. In COMPANION‑002, 31 of 57 patients in the control arm crossed over to receive tovecimig. That crossover is good from an ethics standpoint, but it makes clean survival comparisons almost impossible. Post‑hoc crossover analyses suggest a survival benefit among patients who actually received the drug, yet those are exactly the kinds of analyses the FDA tends to poke hard.
Despite that, major shops are not walking away from CMPX. Leerink said the progression‑free and overall survival package still supports a viable regulatory path in a high‑unmet‑need setting and reiterated an Outperform view. H.C. Wainwright stuck with a Buy and an aggressive $24 target, calling the selloff a misread ahead of a planned pre‑BLA meeting with the FDA around mid‑2026. Jefferies labeled the 61–63% slide an over‑reaction and kept a $9 target, pointing to positive survival signals once you factor in the crossover.
More cautious takes are showing up, too. Stifel cut its CMPX target from $12 to $6 but stayed Buy, leaning on the secondary endpoints and early‑stage pipeline. Canaccord trimmed from $13 to $7, warning that while PFS is clearly better with tovecimig, the crossover muddies survival enough to make full approval uncertain. Wedbush dropped its target from $8 to $5 but maintained Outperform, while Raymond James moved CMPX down to Market Perform. Even so, consensus targets cluster in the $11–$14 range versus a roughly $2 handle, which is why speculative biotech traders are glued to this tape.
Conclusion
For active traders, CMPX is a live case study in how clinical nuance and trading psychology collide. On one side, Compass Therapeutics has a drug that improves response and progression‑free survival in a deadly cancer, runs with an acceptable safety profile, and sits in a tiny, high‑unmet‑need market where regulators sometimes show flexibility. On the other side, the trial missed a key overall survival endpoint in the cleanest analysis, and the heavy crossover leaves the FDA a lot of room to demand more data or limit any approval path.
Right now, the CMPX chart reflects fear, not fine print. The stock crashed more than 60%, then started to base around the high‑$1s as traders digest analyst notes and model scenarios around that mid‑2026 pre‑BLA meeting. Compass Therapeutics’ strong cash position and low debt buy it time, but they do not erase the binary nature of the next major FDA interaction.
For short‑term players, CMPX is all about trading the volatility and respecting risk. For longer‑term, research‑driven traders, the focus shifts to reading every new data cut and regulatory hint. As Tim Sykes likes to remind his students, “The market doesn’t care about your opinion, only the price action and the catalyst.” As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. CMPX has both in abundance right now, making Compass Therapeutics a textbook ticker for traders who study hard, size small, and cut losses fast.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.